doi: 10.1016/s0140-6736(85)90743-3.
Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
- PMID: 2866293
- DOI: 10.1016/s0140-6736(85)90743-3
Item in Clipboard
Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine
Lancet.
.
Abstract
It is postulated that Parkinson's disease is the result of environmental factors acting on genetically susceptible individuals against a background of normal ageing. Many potentially neurotoxic xenobiotics are detoxified by hepatic cytochrome P450. The function of one such system was studied in forty patients with Parkinson's disease and forty normal control subjects. Significantly more parkinsonian than control subjects had partially or totally defective 4-hydroxylation of debrisoquine. Poor metabolisers of debrisoquine tended to have had earlier onset of disease.
Similar articles
-
[Hydroxylation of debrisoquin in Parkinson's disease].Presse Med. 1990 May 19;19(20):947-9. Presse Med. 1990. PMID: 2141131 French.
-
Oxidative polymorphism of debrisoquine in Parkinson's disease.J Neurol Neurosurg Psychiatry. 1990 Apr;53(4):289-92. doi: 10.1136/jnnp.53.4.289. J Neurol Neurosurg Psychiatry. 1990. PMID: 2341841 Free PMC article.
-
Smoking, cancer, and Parkinson's disease.Ann Neurol. 1986 Jul;20(1):105-6. doi: 10.1002/ana.410200120. Ann Neurol. 1986. PMID: 3740811 No abstract available.
-
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
-
Liver enzyme abnormalities in Parkinson's disease.Geriatrics. 1991 Aug;46 Suppl 1:60-3. Geriatrics. 1991. PMID: 1894148 Review.
Cited by
-
Polymorphic sparteine metabolism and amyotrophic lateral sclerosis.J Neurol. 1989 Dec;236(8):452-5. doi: 10.1007/BF00328505. J Neurol. 1989. PMID: 2614489
-
Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.Clin Pharmacokinet. 2004;43(11):693-706. doi: 10.2165/00003088-200443110-00001. Clin Pharmacokinet. 2004. PMID: 15301574 Review.
-
Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells.Gene Expr. 2003;11(3-4):117-24. doi: 10.3727/000000003108749017. Gene Expr. 2003. PMID: 14686785 Free PMC article.
-
Expression analysis of the mixed function oxidase system in rat brain by the polymerase chain reaction.Mol Cell Biochem. 1993 Mar 24;120(2):171-9. doi: 10.1007/BF00926090. Mol Cell Biochem. 1993. PMID: 8487757
-
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37. doi: 10.1007/s00210-003-0832-2. Epub 2003 Nov 15. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 14618296 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
